Analysis of circulating tumor DNA: a new concept in clinical oncology

Analysis of circulating tumor DNA: a new concept in clinical oncology

Show other versions (1)

In recent years ,scientific and technological oncologie advances had allowed the emergence of a new concept which tends to become a new model in medicine; personalized medicine, capable to analyze the genomic specificities of each individual, to better meet their needs. Indeed, it is currently poss...

Full description

Bibliographic Details
Main Authors:	Mourad NACHI, Ibtissem KIHEL
Format:	Article
Language:	English
Published:	University of Oran 1 2021-12-01
Series:	Journal de la Faculté de Médecine d'Oran
Subjects:	Liquid biopsy ctDNA NS-CLC CRC Breast cancer
Online Access:	https://confajol3.ajol.info/index.php/jmfo/article/view/413

Similar Items

Analysis of circulating tumor DNA: a new concept in clinical oncology
by: Mourad NACHI, et al.
Published: (2021-12-01)

Copy Number Variations as Determinants of Colorectal Tumor Progression in Liquid Biopsies
by: Jessica Debattista, et al.
Published: (2023-01-01)

Using cfDNA and ctDNA as Oncologic Markers: A Path to Clinical Validation
by: Jonathan Dao, et al.
Published: (2023-08-01)

Liquid Biopsy in Colorectal Cancer: Quo Vadis? Implementation of Liquid Biopsies in Routine Clinical Patient Care in Two German Comprehensive Cancer Centers
by: Laura E. Fischer, et al.
Published: (2022-05-01)

Circulating Tumor DNA as a Cancer Biomarker: An Overview of Biological Features and Factors That may Impact on ctDNA Analysis
by: Estela Sánchez-Herrero, et al.
Published: (2022-07-01)

Evolving Applications of Circulating Tumor DNA in Merkel Cell Carcinoma
by: Varsha Prakash, et al.
Published: (2023-01-01)

Circulating Tumor DNA and Management of Colorectal Cancer
by: Matthew Krell, et al.
Published: (2023-12-01)

Role of Circulating Tumor DNA in Hematological Malignancy
by: Miho Ogawa, et al.
Published: (2021-04-01)

Genome-wide methylation analysis of circulating tumor DNA: A new biomarker for recurrent glioblastom
by: Lin Dai, et al.
Published: (2023-03-01)

What Is Known about Theragnostic Strategies in Colorectal Cancer
by: Alessandro Parisi, et al.
Published: (2021-02-01)

Circulating Tumor DNA Testing Opens New Perspectives in Melanoma Management
by: Alessandra Sacco, et al.
Published: (2020-10-01)

The Role of ctDNA in Gastric Cancer
by: Justin Mencel, et al.
Published: (2022-10-01)

Mutated circulating tumor DNA as a liquid biopsy in lung cancer detection and treatment
by: Martyna Filipska, et al.
Published: (2021-06-01)

The Use of ctDNA in the Diagnosis and Monitoring of Hepatocellular Carcinoma—Literature Review
by: Agnieszka Kopystecka, et al.
Published: (2023-05-01)

Cell-Free Tumor DNA (ctDNA) Utility in Detection of Original Sensitizing and Resistant EGFR Mutations in Non-Small Cell Lung Cancer (NSCLC)
by: Jason S. Agulnik, et al.
Published: (2022-02-01)

Liquid profiling of circulating tumor DNA in colorectal cancer: steps needed to achieve its full clinical value as standard care
by: Maren Hedtke, et al.
Published: (2022-05-01)

Utilization of Circulating Tumor Cells in the Management of Solid Tumors
by: Peter C. Kurniali, et al.
Published: (2023-04-01)

Accuracy of minimal residual disease detection by circulating tumor DNA profiling in lung cancer: a meta-analysis
by: Ran Zhong, et al.
Published: (2023-05-01)

Liquid Biopsy in Glioblastoma: Opportunities, Applications and Challenges
by: Ander Saenz-Antoñanzas, et al.
Published: (2019-07-01)

BC-Monitor: Towards a Routinely Accessible Circulating Tumor DNA-Based Tool for Real-Time Monitoring Breast Cancer Progression and Treatment Effectiveness
by: Katalin Priskin, et al.
Published: (2021-07-01)

Liquid biopsy evaluation of circulating tumor DNA, miRNAs, and cytokines in meningioma patients
by: Veronica Aran, et al.
Published: (2024-01-01)

Clinical Evidence of Circulating Tumor DNA Application in Aggressive Breast Cancer
by: Brahim El Hejjioui, et al.
Published: (2023-01-01)

Concordance of Targeted Sequencing from Circulating Tumor DNA and Paired Tumor Tissue for Early Breast Cancer
by: Chi-Cheng Huang, et al.
Published: (2023-09-01)

The evidence base for circulating tumour DNA blood-based biomarkers for the early detection of cancer: a systematic mapping review
by: Ian A. Cree, et al.
Published: (2017-10-01)

Use of Circulating Tumour DNA (ctDNA) for Measurement of Therapy Predictive Biomarkers in Patients with Cancer
by: Michael J. Duffy, et al.
Published: (2022-01-01)

Circulating Tumor DNA Mutations in Progressive Gastrointestinal Stromal Tumors Identify Biomarkers of Treatment Resistance and Uncover Potential Therapeutic Strategies
by: Tun Kiat Ko, et al.
Published: (2022-02-01)

Discovery of Targetable Genetic Alterations in NSCLC Patients with Different Metastatic Patterns Using a MassARRAY-Based Circulating Tumor DNA Assay
by: Yassine Belloum, et al.
Published: (2020-10-01)

Can Liquid Biopsy Based on ctDNA/cfDNA Replace Tissue Biopsy for the Precision Treatment of EGFR-Mutated NSCLC?
by: Yi-Ze Li, et al.
Published: (2023-02-01)

Validation of liquid biopsy: plasma cell-free DNA testing in clinical management of advanced non-small cell lung cancer
by: Veldore VH, et al.
Published: (2018-01-01)

Circulating Tumor DNA in Gastric Adenocarcinoma: Future Clinical Applications and Perspectives
by: Giulia Grizzi, et al.
Published: (2023-05-01)

Required Evidence for Clinical Applications of Liquid Biopsy Using Especially CTCs in Lung Cancer
by: Menno Tamminga, et al.
Published: (2020-05-01)

The Use of Circulating Tumor DNA to Monitor and Predict Response to Treatment in Colorectal Cancer
by: Mifanwy Reece, et al.
Published: (2019-11-01)

Liquid biopsy in mice bearing colorectal carcinoma xenografts: gateways regulating the levels of circulating tumor DNA (ctDNA) and miRNA (ctmiRNA)
by: Jessica Gasparello, et al.
Published: (2018-06-01)

Role of ctDNA in Breast Cancer
by: Marta Sant, et al.
Published: (2022-01-01)

Methylated Circulating Tumor DNA in Blood as a Tool for Diagnosing Lung Cancer: A Systematic Review and Meta-Analysis
by: Morten Borg, et al.
Published: (2023-08-01)

Prognostic Value of Circulating Tumor DNA (ctDNA) in Oncogene-Driven NSCLC: Current Knowledge and Future Perspectives
by: Eleni Zografos, et al.
Published: (2022-10-01)

Molecular screening with liquid biopsy for anti-EGFR retreatment in metastatic colorectal cancer: preliminary data from the randomized phase 2 PARERE trial
by: Marco Maria Germani, et al.
Published: (2024-02-01)

Clinicopathological Profiles Associated with Discordant <i>RAS</i> Mutational Status between Liquid and Tissue Biopsies in a Real-World Cohort of Metastatic Colorectal Cancer
by: Elena Brozos-Vázquez, et al.
Published: (2023-07-01)

Role of Circulating Tumor DNA in Gastrointestinal Cancers: Update From Abstracts and Sessions at ASCO 2018
by: Faisal Shahjehan, et al.
Published: (2019-05-01)

Intra-Patient Heterogeneity of Circulating Tumor Cells and Circulating Tumor DNA in Blood of Melanoma Patients
by: Katharina Gorges, et al.
Published: (2019-10-01)